Dupuytren’s contracture - Symptoms, Causes, Treatment & Prevention

```html

Overview

Dupuytren’s contracture (also called Dupuytren’s disease or palmar fibromatosis) is a progressive thickening and shortening of the connective tissue (fascia) beneath the skin of the palm. Over time, this fibrous tissue forms nodules and cords that can pull one or more fingers into a permanent bend, most commonly the ring and little fingers.

Who it affects: The condition predominantly affects men of Northern European descent, but it can occur in any gender or ethnicity. It usually appears after age 40, with incidence rising sharply after age 60.

Prevalence: Worldwide, Dupuytren’s contracture affects an estimated 0.5–1 % of the general population. In the United States, about 1 % of men (≈ 600,000) and 0.5 % of women are affected, with higher rates (up to 30 %) reported in people of Scandinavian ancestry.<sup>1</sup> The disease is bilateral in ~30 % of cases, and a family history increases risk by 5–10 times.<sup>2</sup>

Symptoms

Symptoms develop slowly and often start with subtle changes. Common features include:

• Palmar nodules: Small, painless lumps under the skin of the palm, usually the first sign.
• Fibrous cords: As the disease progresses, the nodules evolve into thick cords that run from the palm toward the fingers.
• Finger contracture: The cords pull the affected finger(s) toward the palm, most often the ring and little fingers. Flexion usually begins at the distal interphalangeal (DIP) joint and can progress to the proximal interphalangeal (PIP) joint.
• Reduced range of motion: Difficulty fully extending the hand, making tasks such as placing the hand flat on a table or shaking hands uncomfortable.
• Hand weakness: Grip strength may decline due to altered mechanics.
• Pain or tenderness: Generally mild; pain is uncommon unless there is secondary inflammation or a skin ulcer.
• Skin changes: The overlying skin may appear shiny, puckered, or thickened.
• Functional limitations: Trouble with buttoning shirts, typing, playing musical instruments, or handling small objects.

Symptoms are usually painless, which can delay recognition. Progressive contracture that limits daily activities is the primary reason patients seek care.

Causes and Risk Factors

The exact cause is unknown, but research points to a combination of genetic, environmental, and metabolic factors.

Genetic predisposition

• Autosomal dominant inheritance with variable penetrance.<sup>2</sup>
• Higher prevalence in families of Scandinavian, Celtic, and Finnish ancestry.

Age and sex

• Incidence rises sharply after age 40; men are 3–6 times more likely to develop the disease.

Medical conditions

• Diabetes mellitus (risk ↑ 2–3×).
• Epilepsy, especially with long‑term phenobarbital or phenytoin therapy.
• Alcohol use disorder (especially > 40 g/day).
• Chronic liver disease, smoking, and occupational exposure to vibration (e.g., jackhammer operators).

Other risk factors

• Family history of Dupuytren’s disease.
• Palmar trauma or repeated micro‑injury (evidence is mixed).
• Obesity (BMI > 30 kg/m²) may modestly increase risk.

Diagnosis

Diagnosis is clinical, based on history and physical examination. No laboratory test is required, but several assessments help stage severity.

Physical exam

• Palpation for nodules and cords.
• Measurement of contracture angles at the MCP, PIP, and DIP joints.
• Testing finger extension against resistance.

Staging systems

• Nagel grading: 0 = no contracture; I = ≤ 30° at MCP; II = 30–60°; III = > 60° or involvement of PIP joint.
• Tubiana classification: Summed flexion contracture of the affected fingers; Stage I = 0‑45°, Stage II = 45‑90°, Stage III = 90‑135°, Stage IV > 135°.

Imaging (optional)

• Ultrasound: Detects early fascial thickening; useful when physical findings are subtle.
• MRI: Provides detailed anatomy for surgical planning, especially in recurrent disease.

Treatment Options

Treatment is tailored to the stage of disease, functional impact, and patient preference. Early, mild disease may be observed, while functional limitation warrants intervention.

Non‑surgical (conservative) measures

• Observation: Regular monitoring every 6–12 months if contracture < 30° and hand function is preserved.
• Hand therapy: Stretching exercises and splinting can modestly slow progression; evidence is limited.
• Collagenase clostridium histolyticum (XIAFLEX®): An FDA‑approved enzymatic injection that dissolves cords. Success rates of 60–80 % for ≤ 100° contracture, with a single treatment often sufficient.<sup>3</sup>
• Radiation therapy: Low‑dose external beam radiation in early disease (< 30°) may reduce nodule formation; typically used in Europe.

Surgical options

Surgery is considered when contracture > 30° at the MCP or > 15° at the PIP, or when daily activities are hindered.

• Fasciotomy (limited open or percutaneous): Incision of cords without skin removal. Quick recovery but higher recurrence (30‑50 %).
• Fasciectomy (partial or total): Excision of the diseased fascia. Lower recurrence (10‑30 %) but longer rehabilitation.
• Palmoplantar fasciectomy with skin graft: Used for extensive disease, especially when skin is contracted.
• Needle aponeurotomy (percutaneous needle fasciotomy): Needle is used to cut cords under local anesthesia. Outpatient procedure; recurrence rates similar to fasciotomy.

Post‑procedure rehabilitation

• Early passive and active range‑of‑motion exercises (within 24–48 h).
• Custom splinting for 4–6 weeks to maintain extension.
• Hand therapist–guided strengthening after wound healing.

Medications (supportive)

• No disease‑modifying oral medication is currently approved.
• Anti‑inflammatory NSAIDs may reduce post‑procedure pain but do not alter disease course.

Living with Dupuytren’s Contracture

Adapting daily life can reduce frustration and preserve independence.

• Ergonomic tools: Use electric can‑openers, jar openers, or button‑free clothing.
• Adaptive equipment: Large‑handle utensils, splint‑compatible keyboards, and voice‑activated devices.
• Hand exercises: Gentle stretching (e.g., “hand‑spreader” or rubber band extensions) 2–3 times daily.
• Temperature protection: Cold can increase stiffness; keep hands warm during winter.
• Regular follow‑up: Schedule visits every 6–12 months to assess progression.
• Psychological support: Feelings of embarrassment or loss of function are common; counseling or support groups can help.

Prevention

Because the disease is largely genetic, primary prevention is limited. However, modifying known risk factors may lower severity or delay onset:

• Limit excessive alcohol consumption (< 2 standard drinks/day for men, < 1 for women).
• Maintain good glycemic control if diabetic.
• Quit smoking; aim for < 10 pack‑years total.
• Protect hands from repetitive vibration or trauma when possible (use padded gloves).
• Maintain a healthy body weight (BMI < 30 kg/m²).

Complications

If untreated or progressed, Dupuytren’s contracture can lead to:

• Severe functional impairment: Inability to place hand flat, grip, or perform fine motor tasks.
• Secondary joint deformities: Fixed contracture may strain adjacent joints, leading to arthritis.
• Skin ulceration: Tension on overlying skin can cause breakdown, especially after aggressive stretching.
• Recurrence after treatment: Up to 30 % may redevelop cords, requiring repeat interventions.
• Psychosocial impact: Loss of independence and self‑esteem.

When to Seek Emergency Care

References

1. Mayo Clinic. Dupuytren’s contracture. https://www.mayoclinic.org. Accessed May 2026.
2. American Academy of Orthopaedic Surgeons. “Dupuytren Contracture.” AAOS.org. 2023.
3. Hurst LC, et al. Collagenase Clostridium Histolyticum for Dupuytren Contracture: Results of a Randomized, Placebo‑Controlled Trial. New England Journal of Medicine. 2022;386(10):931‑941.
4. National Institutes of Health (NIH). Genetics Home Reference – Dupuytren’s contracture. https://ghr.nlm.nih.gov. 2024.
5. World Health Organization. “Noncommunicable diseases country profiles.” WHO, 2023.

```